Bausch + Lomb names Thomas Appio interim CEO, signals guidance hike
- Bausch + Lomb (BLCO:CA) appointed chairman Thomas J. Appio as interim CEO, effective immediately, while he continues to lead parent company Bausch Health (BHC:CA).
- Appio was appointed chairman of the Bausch + Lomb Board of Directors in August 2026. “The opportunity to lead Bausch + Lomb is both a privilege and a responsibility that I embrace with great enthusiasm,” said Appio.
- Appio has served as CEO of Bausch Health since 2022.
- Brent Saunders, who has served as Bausch + Lomb CEO since 2023, and the Board of Directors mutually agreed that Saunders will depart the company.
- Based on preliminary third-quarter results, Bausch + Lomb and Bausch Health currently expect to raise full-year 2026 adjusted EBITDA excluding acquired IPR&D guidance. The companies are currently in a blackout period and will provide additional details when they report third-quarter results on Oct. 28.
Recommended For You
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
Register for free to keep reading.
Create a free account to get unlimited breaking news and alerts when your stocks move.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.